Summary
20.90 -0.14(-0.67%)09/18/2024
Xencor Inc (XNCR)
Xencor Inc (XNCR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.67 | -0.95 | 23.30 | 7.73 | -6.00 | 1.26 | -41.91 | 150.60 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 20.90 | |
| Open | 21.04 | |
| High | 21.56 | |
| Low | 20.53 | |
| Volume | 335,102 | |
| Change | -0.14 | |
| Change % | -0.67 | |
| Avg Volume (20 Days) | 628,706 | |
| Volume/Avg Volume (20 Days) Ratio | 0.53 | |
| 52 Week Range | 15.33 - 26.84 | |
| Price vs 52 Week High | -22.13% | |
| Price vs 52 Week Low | 36.33% | |
| Range | -0.67 | |
| Gap Up/Down | -0.61 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,441 | |
| EBIDTA | 27,509,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 54.64 | |
| Book Value | 10.5870 | |
| Earnings Per Share | -0.0720 | |
| EPS Estimate Current Quarter | -0.6500 | |
| EPS Estimate Next Quarter | -0.4100 | |
| EPS Estimate Current Year | 0.1400 | |
| EPS Estimate Next Year | -2.2900 | |
| Diluted EPS (TTM) | -0.0720 | |
| Revenues | ||
| Profit Marging | -0.0253 | |
| Operating Marging (TTM) | -0.3746 | |
| Return on asset (TTM) | -0.0568 | |
| Return on equity (TTM) | -0.0069 | |
| Revenue TTM | 162,950,000 | |
| Revenue per share TTM | 2.8070 | |
| Quarterly Revenue Growth (YOY) | -0.4430 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -47,108,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.1931 | |
| Revenue Enterprise Value | 10.5683 | |
| EBITDA Enterprise Value | 68.8721 | |
| Shares | ||
| Shares Outstanding | 58,481,600 | |
| Shares Float | 53,256,817 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 1.55 | |
| Institutions (%) | 101.46 | |
09/12 16:01 EST - businesswire.com
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the closing of its previously announced underwritten public offering of 8,093,712 shares of its common stock at a price to the public of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,458,600 additional shares of.
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the closing of its previously announced underwritten public offering of 8,093,712 shares of its common stock at a price to the public of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,458,600 additional shares of.
09/12 08:16 EST - seekingalpha.com
Xencor: Vudalimab Development Along With Hidden Gem Candidate
Monotherapy and combination dose cohort data from the phase 2 study, using vudalimab for the treatment of patients with mCRPC, expected 1st half of 2025. The global metastatic castrate-resistant prostate cancer treatment market size is projected to reach $20.70 billion by 2031. XmAb942 is a candidate in the company's pipeline which has the potential to become the best in class anti-TL1A inhibitor for the treatment of autoimmune disorders like UC and CD.
Xencor: Vudalimab Development Along With Hidden Gem Candidate
Monotherapy and combination dose cohort data from the phase 2 study, using vudalimab for the treatment of patients with mCRPC, expected 1st half of 2025. The global metastatic castrate-resistant prostate cancer treatment market size is projected to reach $20.70 billion by 2031. XmAb942 is a candidate in the company's pipeline which has the potential to become the best in class anti-TL1A inhibitor for the treatment of autoimmune disorders like UC and CD.
09/12 05:55 EST - zacks.com
Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
09/10 13:25 EST - zacks.com
Xencor Stock Gains 23% on Encouraging Pipeline Advancements
XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates.
Xencor Stock Gains 23% on Encouraging Pipeline Advancements
XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates.
09/09 07:31 EST - businesswire.com
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced four new XmAb® programs in development for the treatment of patients with autoimmune diseases and provided updates from dose-escalation studies evaluating its first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and.
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced four new XmAb® programs in development for the treatment of patients with autoimmune diseases and provided updates from dose-escalation studies evaluating its first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and.
08/05 18:15 EST - zacks.com
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.37 per share a year ago.
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.37 per share a year ago.
06/13 08:01 EST - businesswire.com
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase 1 clinical development in hematologic cancers. In 2021, Xencor entered a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercial.
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase 1 clinical development in hematologic cancers. In 2021, Xencor entered a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercial.
05/09 16:09 EST - businesswire.com
Xencor Reports First Quarter 2024 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights. “We have focused our XmAb® clinical pipeline and discovery activities on bispecific CD3 and CD28 T cell engagers, which continue to show clinical validation for t.
Xencor Reports First Quarter 2024 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights. “We have focused our XmAb® clinical pipeline and discovery activities on bispecific CD3 and CD28 T cell engagers, which continue to show clinical validation for t.
05/06 11:01 EST - zacks.com
Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
05/02 04:35 EST - zacks.com
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
04/09 08:01 EST - businesswire.com
Xencor Appoints Bart Cornelissen as Chief Financial Officer
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance.
Xencor Appoints Bart Cornelissen as Chief Financial Officer
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance.
02/28 00:35 EST - seekingalpha.com
Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript
Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript
Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript
Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript
02/27 18:21 EST - zacks.com
Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of $0.36. This compares to loss of $0.20 per share a year ago.
Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of $0.36. This compares to loss of $0.20 per share a year ago.
02/27 16:01 EST - businesswire.com
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a review of recent business and clinical highlights. The Company also presented encouraging early clinical data from its Phase 2 study of vudalimab monotherapy for patients with clinically defined.
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a review of recent business and clinical highlights. The Company also presented encouraging early clinical data from its Phase 2 study of vudalimab monotherapy for patients with clinically defined.
02/20 16:31 EST - businesswire.com
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results, provide a.
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results, provide a.
02/19 04:41 EST - zacks.com
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
02/15 11:07 EST - zacks.com
Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
01/03 16:01 EST - businesswire.com
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 at 3:45 p.m. PST. A live webcast of the presentation will be available under "Events & Presentations" in the Investors s.
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 at 3:45 p.m. PST. A live webcast of the presentation will be available under "Events & Presentations" in the Investors s.
01/03 11:16 EST - zacks.com
Xencor (XNCR) Soars 6.0%: Is Further Upside Left in the Stock?
Xencor (XNCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Xencor (XNCR) Soars 6.0%: Is Further Upside Left in the Stock?
Xencor (XNCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
01/02 08:01 EST - businesswire.com
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Dane Leone, CFA, has joined Xencor as senior vice president, corporate strategy. In this newly created role, Mr. Leone will support the Company's R&D leadership to enhance value across Xencor's platform technologies by overseeing assessment and prioritization of Xenco.
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Dane Leone, CFA, has joined Xencor as senior vice president, corporate strategy. In this newly created role, Mr. Leone will support the Company's R&D leadership to enhance value across Xencor's platform technologies by overseeing assessment and prioritization of Xenco.